Comparison of the influence of CYP2C19 polymorphism on the effect of rabeprazole and omeprazole during the early healing phase of gastric ulcer

被引：0
|
作者：
Ando, T
Kato, H
Kajikawa, H
Isozaki, Y
Sugimoto, N
Seto, N
Nagao, Y
Hongo, H
Furuki, T
Takamori, S
Shimozawa, M
Yoshikawa, T
机构：
来源：
GASTROENTEROLOGY | 2002年 / 122卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W827
引用
收藏
页码：A514 / A514
页数：1
相关论文
共 50 条
  • [31] Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans
    Hu, Yong-Mei
    Mei, Qiao
    Xu, Xin-Hua
    Hu, Xiang-Peng
    Hu, Nai-Zhong
    Xu, Jian-Ming
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (29) : 4750 - 4753
  • [32] The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole
    Bekkers, CHJ
    Touw, DJ
    Lamers, CBHW
    Geus, WP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 553 - 553
  • [33] Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans
    Yong-Mei Hu
    World Journal of Gastroenterology, 2006, (29) : 4750 - 4753
  • [34] The CYP2C19 enzyme polymorphism
    Wedlund, PJ
    PHARMACOLOGY, 2000, 61 (03) : 174 - 183
  • [35] Effect of clarithromycin on metabolism of omeprazole with relation to CYP2C19 status
    Furuta, T
    Kobayashi, K
    Takashima, M
    Hanai, H
    Chiba, K
    Ohashi, K
    Kaneko, TE
    GUT, 1998, 43 : A109 - A109
  • [36] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people
    Hu, Xiang-Peng
    Xu, Jian-Ming
    Hu, Yong-Mei
    Mei, Qiao
    Xu, Xin-Hua
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (05) : 517 - 524
  • [37] Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
    Sagar, M
    Tybring, G
    Dahl, ML
    Bertilsson, L
    Seensalu, R
    GASTROENTEROLOGY, 2000, 119 (03) : 670 - 676
  • [38] Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism
    Hokari, K
    Sugiyama, T
    Kato, M
    Saito, M
    Miyagishima, T
    Kudo, M
    Nishikawa, K
    Ishizuka, J
    Komatsu, Y
    Mizushima, T
    Kagaya, H
    Hige, S
    Takeda, H
    Asaka, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (09) : 1479 - 1484
  • [39] A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism
    Miyoshi, M
    Mizuno, M
    Ishiki, K
    Nagahara, Y
    Maga, T
    Torigoe, T
    Nasu, J
    Okada, H
    Yokota, K
    Oguma, K
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (07) : 723 - 728
  • [40] CYP2C19 genotype status and dual therapy with omeprazole and amoxicillin for eradication of Helicobacter pylori and peptic ulcer healing.
    Furuta, T
    Ohashi, K
    Kamata, T
    Takashima, M
    Hanai, H
    Kosuge, K
    Kubota, T
    Ishizaki, T
    Kaneko, E
    GASTROENTEROLOGY, 1998, 114 (04) : A127 - A127
12345